Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024

SAN JOSE, Calif., April 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024. Anixa Chairman and CEO Dr. Amit Kumar will present an overview of the Company and its clinical programs including vaccines to prevent cancer and a CAR-T cell therapy to treat cancer.

Conference details:

Presentation:                                  Thursday, May 9, 2024, at 11:30 am ET*
Presentation link:                          Click here to register; available via Zoom
Conference registration:              Available on the conference website
1x1 meetings:                                     Open to all investors upon conference registration

Dr. Kumar will discuss Anixa's preventative breast cancer vaccine, currently in Phase 1 clinical trials, that is showing strong positive data. Additional data releases expected in the coming months, and a Phase 2 trial is expected to commence in early 2025. Anixa's CAR-T cell therapy treatment for ovarian cancer is also in a Phase 1 trial and showing positive data. Anixa has a capital efficient business model, with greater than two years cash, no debt, and a clean cap table.

*The presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer ? specifically triple negative breast cancer (TNBC), the most lethal form of the disease ? as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10- Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward- looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808

SOURCE Anixa Biosciences, Inc.